Weekly Investment Analysts’ Ratings Updates for AnaptysBio (ANAB)

Several brokerages have updated their recommendations and price targets on shares of AnaptysBio (NASDAQ: ANAB) in the last few weeks:

• 2/4/2025 – AnaptysBio is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $25.00 price target on the stock.
• 2/4/2025 – AnaptysBio had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
• 2/3/2025 – AnaptysBio was upgraded by analysts at Wolfe Research to a “strong-buy” rating.
• 2/3/2025 – AnaptysBio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $40.00 price target on the stock.
• 12/19/2024 – AnaptysBio had its price target lowered by analysts at JPMorgan Chase & Co. from $66.00 to $36.00. They now have an “overweight” rating on the stock.
• 12/18/2024 – AnaptysBio had its price target lowered by analysts at Truist Financial Co. from $30.00 to $20.00. They now have a “hold” rating on the stock.
• 12/12/2024 – AnaptysBio had its price target lowered by analysts at Wells Fargo & Company from $56.00 to $40.00. They now have an “overweight” rating on the stock.
• 12/12/2024 – AnaptysBio had its price target lowered by analysts at Guggenheim from $90.00 to $36.00. They now have a “buy” rating on the stock.
• 12/11/2024 – AnaptysBio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $40.00 price target on the stock, down previously from $42.00.
• 12/11/2024 – AnaptysBio was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. They now have a $19.00 price target on the stock, down previously from $52.00.

AnaptysBio Price Performance

Shares of NASDAQ ANAB opened at $16.08 on Friday. AnaptysBio, Inc. has a 1 year low of $12.51 and a 1 year high of $41.31. The stock has a market capitalization of $489.30 million and a P/E ratio of -2.64. The company has a 50-day moving average price of $16.87 and a 200-day moving average price of $26.69.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. As a group, equities research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Ecor1 Capital, Llc purchased 6,646 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were acquired at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the acquisition, the director now owns 7,880,094 shares in the company, valued at $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 33.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds have recently modified their holdings of ANAB. Values First Advisors Inc. purchased a new stake in shares of AnaptysBio during the third quarter valued at approximately $49,000. nVerses Capital LLC grew its stake in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of AnaptysBio by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 644 shares during the last quarter. Point72 DIFC Ltd raised its stake in shares of AnaptysBio by 680.5% during the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 5,342 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of AnaptysBio by 35.0% in the 4th quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock worth $216,000 after buying an additional 4,231 shares during the last quarter.

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.